A growing body of observational research links four common drug classes to higher dementia risk, prompting pharmacists and insurers to reassess prescribing habits. Anticholinergic antihistamines—found in over‑the‑counter sleep aids and allergy pills—show the strongest signal, with several studies estimating a 50% increase in dementia incidence among long‑term daily users. Experts caution that occasional use remains low risk for older adults and caregivers should be aware.

Antipsychotics and benzodiazepines also draw scrutiny. Researchers debate whether the drugs themselves or the underlying conditions—such as depression, psychosis or anxiety—drive the association, but data link antipsychotic use to faster cognitive decline and higher mortality in dementia patients. A University of Southern California analysis isolated benzodiazepine prescriptions for back pain and found no measurable rise in dementia diagnoses, tempering earlier alarms.

Proton pump inhibitors (PPIs) remain controversial; some cohorts suggest a modest risk boost, while randomized trials with pantoprazole found no effect over three years. Because PPIs are widely sold OTC, usage data are fragmented, complicating risk assessments for insurers and retailers. The mixed evidence urges clinicians to weigh gastrointestinal benefits against uncertain cognitive costs before defaulting to long‑term PPI therapy.